Advances in our knowledge of CD40 biology combined with results and immune correlate material from early-stage clinical trials will inevitably provide opportunities to promote the outcomes of CD40 stimulation whether in combination with traditional cancer vaccines or with interventions that result in autovaccination. This evidence concerns the gene CD40 and cancer.